Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Interest Income

Income earned on cash, deposits, and investments held by the company.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $4.1M fell 37.7% year over year, behind the -35.4% change in trailing-twelve-month interest income. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at +49.8% a year.

Context

  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -37.7% toward the trailing-twelve-month pace of -35.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.1M-11.2% QoQ
Last fiscal yearDec 2025
$22.21M-25.1% YoY
LTMMar 2026
$19.73M-35.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.7%——
1 year-25.1%——
3-year CAGR+49.8%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
22.21M USD
Year-over-year change
-25.1%
4-year CAGR
+161.2%

Interest Income vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.4% is the 7th highest of 11, against a peer median of -27.0%.
  • Over three fiscal years its annual growth of +49.8% compares with a peer median of +69.9%.
CGEM Competitors
Interest Income for CGEM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JANXJanux Therapeutics, Inc.LTM Mar 2026$66.09M USD+84.4%+121.9%305.8%
LEGNLegend Biotech CorporationLTM Sep 2026$23.55M USD-48.6%+69.9%1.7%
XNCRXencor, Inc.LTM Jun 2026$23M USD-24.6%+78.8%21.9%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$19.73M USD-35.4%+49.8%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$18.56M USD-20.1%+84.3%2.6%
IMTXImmatics N.V.LTM Mar 2026€15.3M EUR-36.7%+90.7%41.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$11.63M USD-10.2%——
ADCTADC Therapeutics S.A.LTM Mar 2026$8.75M USD-23.1%+50.8%11.1%
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$3.66M USD-55.5%-2.5%—
CGENCompugen Ltd.LTM Mar 2026$2.66M USD-49.0%+45.3%3.7%
Peer median (excluding CGEM) —-27.0%+69.9%7.4%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.